COMP <GO>
IDXG vs CAT // GROSS PROFIT MARGIN
Interpace Biosciences Inc. (NASDAQ) VS. Caterpillar Inc. (NYSE) • 15-METRIC TALLY: IDXG 5
— CAT 6
▲ GROSS PROFIT MARGIN LEADER: CAT
LAST: $5.72 (+15.56%) • MKT CAP: $23.2M
gross-margins
62.30%
LAST: $647.39 (-9.25%) • MKT CAP: $297.59B
gross-margins
82.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IDXG VS. CAT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IDXG | CAT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 62.30% | 82.20% | -19.90 | CAT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.20% | 21.15% | -4.95 | CAT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.7x | 20.9x | -16.16 | IDXG | /valuation <GO> |
| Free Cash Flow Yield | 23.60% | 3.74% | +19.86 | IDXG | /fcf-yield <GO> |
| Operating Margin | 10.50% | 17.52% | -7.02 | CAT | /operating-margins <GO> |
| Net Profit Margin | 63.50% | 14.51% | +48.99 | IDXG | /net-margins <GO> |
| Revenue Growth (YoY) | -17.50% | 18.36% | -35.86 | CAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.05% | -1.05 | CAT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 4.34 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | IDXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 8.46% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 33.5 | +16.45 | IDXG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.02 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.2M | $297.59B | -$297.57B | CAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IDXG REV | CAT REV | IDXG GROSS % | CAT GROSS % | IDXG FCF | CAT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $38.7M | $67.59B | 62.3% | 99.9% | $5.5M | $8.92B |
| FY 2024 | $46.9M | $64.81B | 63.8% | 100.0% | $3.8M | $10.05B |
| FY 2023 | $40.0M | $67.06B | — | 99.8% | $3.8M | $11.29B |
| FY 2022 | — | $59.43B | — | 99.3% | — | $6.47B |
| FY 2021 | — | $50.97B | — | 30.3% | — | $6.11B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IDXG // BETA —
CAT // BETA 1.02